Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

HypErthermia as an Additional Treatment for the Biology and Experience of Depression

NCT: NCT05041361 · COMPLETED

NCT IDNCT05041361
StatusCOMPLETED
Start Date2021-10-11
Completion2023-03-01

Brief Summary

This single-arm feasibility trial administered up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions to adults aged 18 years or older with major depressive disorder (MDD).

Frequently Asked Questions

What is HypErthermia as an Additional Treatment for the Biology and Experience of Depression?

HypErthermia as an Additional Treatment for the Biology and Experience of Depression is a clinical trial registered under NCT05041361. Current status: COMPLETED.

What is the status of NCT05041361?

The current status of NCT05041361 (HypErthermia as an Additional Treatment for the Biology and Experience of Depression) is: COMPLETED.

When did HypErthermia as an Additional Treatment for the Biology and Experience of Depression start?

HypErthermia as an Additional Treatment for the Biology and Experience of Depression started on 2021-10-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑